Angiodynamics Stock Price, News & Analysis

AngioDynamics (NASDAQ: ANGO) said its NanoKnife System was named to TIME’s 2025 Best Inventions in Medical and Healthcare for its use of Irreversible Electroporation (IRE) to ablate prostate tissue while preserving nearby structures.

The company noted a U.S. FDA 510(k) clearance in late 2024, publication of the PRESERVE study (121 patients, 17 sites) showing 84% free from in-field clinically significant disease at 12 months, 96% pad-free continence preservation, and 84% retention of baseline sexual function. AngioDynamics referenced >2,600 global patients treated and said the TIME issue hits newsstands December 12.

AngioDynamics (NASDAQ: ANGO) reported strong fiscal Q1 2026 results, with net sales reaching $75.7 million, up 12.2% year-over-year. The Med Tech segment showed exceptional performance with 26.1% growth to $35.3 million, marking its fourth consecutive quarter of over 20% growth.

Key financial metrics include a gross margin of 55.3%, adjusted EBITDA of $2.2 million (compared to -$0.2M prior year), and adjusted loss per share of $0.10. The company ended Q1 with $38.8 million in cash and maintains a debt-free balance sheet.

Following strong performance, AngioDynamics raised its FY2026 guidance, now expecting net sales of $308-313 million and Med Tech growth of 14-16%. The company achieved significant clinical milestones with first patient enrollments in both AMBITION BTK and RECOVER-AV trials, while the NanoKnife PRESERVE study results were published in European Urology.

AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has scheduled its fiscal 2026 first quarter financial results announcement for October 2, 2025, before market open.

The company will host a conference call at 8:00 AM ET on the same day, accessible via phone (1-877-407-0784 domestic, +1-201-689-8560 international) and webcast through their investor relations website. A replay will be available until October 9, 2025, using passcode 13755707.

AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular systems and cancer treatment, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Jim Clemmer, President and CEO, and Stephen Trowbridge, EVP and CFO, will conduct a fireside chat presentation on August 12, 2025, at 9:00 a.m. ET.

Investors can access the live webcast through the company's investor relations website at www.angiodynamics.com, where a replay will also be available after the event.

AngioDynamics (NASDAQ: ANGO) has announced the enrollment of its first patient in the AMBITION BTK clinical trial, investigating the effectiveness of their Auryon Atherectomy System combined with balloon angioplasty for treating Critical Limb Ischemia (CLI).

The trial will be a multicenter, randomized controlled study involving up to 224 patients across 30 sites, with a parallel registry enrolling up to 1,500 additional patients. The study aims to evaluate freedom from major amputation, freedom from clinically driven target lesion revascularization, and primary patency at 12 months.

The Auryon laser system has already treated over 100,000 patients worldwide and can address all infrainguinal lesion types. This trial is particularly significant as CLI affects a large patient population, with untreated cases facing a 20-25% risk of limb loss within one year.

AngioDynamics (NASDAQ: ANGO) announced the publication of its PRESERVE study results in European Urology, evaluating the NanoKnife System for prostate tissue ablation. The study, involving 121 patients across 17 clinical sites, demonstrated significant success in treating intermediate-risk prostate cancer.

Key findings include 84% of patients remaining free from clinically significant disease at 12 months post-procedure. The study showed remarkable quality-of-life preservation, with 96% maintaining urinary continence and 84% preserving sexual function. The NanoKnife System, which received FDA clearance for prostate tissue ablation in late 2024, uses non-thermal irreversible electroporation (IRE) technology to provide a minimally invasive treatment option.

AngioDynamics (NASDAQ: ANGO) reported strong Q4 and full fiscal year 2025 results, with notable growth in their Med Tech franchise. Q4 highlights include pro forma net sales of $80.2M (up 12.7% YoY), with Med Tech sales reaching $35.8M (up 22.0%) and Med Device sales at $44.4M (up 6.2%).

For FY2025, the company achieved total net sales of $292.7M (up 8.1% YoY), with Med Tech sales growing 19.5% to $126.7M. The company reported positive adjusted EBITDA of $13.1M for the full year and ended with $55.9M in cash. Key achievements include receiving a CPT Category I Code for NanoKnife's IRE treatment and securing a $25M revolving credit facility.

For FY2026, AngioDynamics projects net sales of $305-310M, with Med Tech growth of 12-15% and expects positive free cash flow, despite anticipated tariff impacts of $4-6M.

AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has scheduled its fiscal 2025 fourth quarter and full-year financial results announcement for Tuesday, July 15, 2025, before market open.

The company will host a conference call at 8:00 am ET on the same day, accessible via phone (1-877-407-0784 domestic, +1-201-689-8560 international) or webcast through the investor relations section of their website. A replay will be available through July 15, 2025, at 11:59 PM ET using passcode 13754203.

AngioDynamics (NASDAQ: ANGO) has announced the enrollment of the first patient in its RECOVER-AV clinical trial, evaluating the AlphaVac F1885 System for treating acute, intermediate-risk pulmonary embolism (PE). This multi-center study follows the system's FDA clearance in April 2024 and CE Mark approval in May 2024. The trial will assess safety, efficacy, and long-term functional outcomes across up to 20 sites in Europe, Canada, and Hong Kong. The study targets a significant medical need, with approximately 435,000 PE events occurring annually in the six largest EU countries. The trial builds on successful results from the U.S. APEX-AV trial, which showed significant improvements in right ventricular function and clot burden reduction. Patients will be monitored for 12 months, with comprehensive assessments including Cardiac MRI and exercise testing.